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Materials and Methods: From 1993 to 2007, 953 patients (median age 
65 years) underwent ADV (n=685) or SALV (n=268) RT with non 
conformal (n=169), 3DCRT (n=658) or IMRT (n=20) technique at 1.80 
Gy/fraction, at a median RT dose of 70.2 Gy, or moderately 
hypofractionated (median 28 fractions) Tomotherapy (n=106) to a 
median 2-Gy equivalent (EQD2, a/b=3) dose of 70 Gy. WPRT was 
delivered to 282 patients at a median of 50 Gy. The median follow-up 
(FU) of pts treated with prostatic bed (PB) only RT was longer (110 vs 
85 months) as compared to the WPRT+PB group.  
Results: After a median FU of 103 months, actuarial 10-year overall 
survival (OS) was 86%. A 2ndNPL arose in 101 patients after a median 
of 46 months from RT (44/101 after >5 years). Thirty-two were 
INFIELD and 69 were OUTFIELD. The 10-year overall risk of 2ndNPL 
was 14% vs 9% (p=0.10) for pts receiving PB only or WPRT+PB, 
respectively (4% vs 2%, p=0.17, for INFIELD and 9% vs 6%, p=0.33, for 
OUTFIELD). Of note, the 10-year risk of 2ndNPL was significantly 
higher (17% vs 11%, p=0.02) in patients experiencing any (acute or 
late) GU toxicity Grade ≥2. Multivariate analysis, which indicated the 
independent predictive role of age >65 year in all subgroups, 
confirmed Grade ≥2 GU toxicity as a significant predictor of the risk of 
overall (HR 2.15, p=0.04) and OUTFIELD (HR 2.10, p=0.04), but not 
INFIELD 2ndNPL. When the analysis was limited to 2ndNPL onset after 
>5 year from RT, diabetes emerged as the only independent predictor 
of overall 2ndNPL (HR 2.19, p=0.048) and age >65 that of OUTFIELD 
ones (HR 1.08, p=0.02), while no factors independently predicted 
INFIELD 2ndNPL (n=13). Overall, 123 pts died, 53 owing to PCa 
progression, 34 to a 2ndNPL and 36 to non neoplastic causes. The 10-
year risk of death was quite similar in pts experiencing a clinical 
relapse of PCa or an INFIELD or OUTFIELD 2ndNPL (40% vs 31% vs 37%, 
respectively, p=0.48) and significantly higher than that (6%) of pts 
bNEDs or with a PSA failure only after RT. Importantly, no role 
emerged for RT dose, technique or fractionation. 
Conclusions: Although preliminary, this study suggests that the 
impact of treating larger volumes with WPRT may be not significant, 
in contrast with the hypothesis of a proportionally higher incidence of 
2ndNPL with the increase of body integral dose. The correlation which 
emerged between GU toxicity and the risk of 2ndNPL deserves further 
investigation.  
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Purpose/Objective: Purpose of this study is to analyze outcomes and 
pre-treatment prognostic factors in high-risk prostate cancer patients 
with initial PSA > 20 ng/mL, treated with high-dose External-Beam 
Radiotherapy (EBRT) and androgen-deprivation therapy (ADT) in a 
single institution. 
Materials and Methods: Between March 2003 and December 2011, 155 
consecutive high-risk prostate cancer patients a) presenting with 
pretreatment PSA level > 20 ng/mL, b) treated with definitive EBRT 
and c) with a minimum follow-up of 24 months were included in this 
retrospective analysis. Phoenix definition was used to define 
biochemical control. Multivariate analysis was performed to 
determine the independent prognostic impact of pre-treatment 
clinical factors (T stage, PSA and Gleason Score [GS]) on clinical 
outcomes (biochemical Disease-Free Survival [bDFS], Distant 
Metastasis Free Survival [DMFS], Cancer-Specific Survival [CSS], 
Overall Survival [OS]). 
Results:  
 
At a median follow-up of 62 months, actuarial bDFS, DMFS, CSS and OS 
at 5 years were 64.8%, 85.2%, 95.8%, and 94.4%, respectively. On 
multivariate analysis, only GS was significantly associated with three 
clinical endpoints (bDFS: HR 1.6; p=0.022, CSS: HR 4.27, p=0.044, OS: 
HR 2.6;p=0.038). Pre-treatment zenith PSA (zPSA) was associated only 
with bDFS (HR 1.87; p=0.027). 
Conclusions: Patients with 'high' PSAl evels (>20 ng/mL) or 'ultra-high' 
PSA levels (> 50 ng/mL) showed favorable clinical outcomes, 
supporting thus the role of local radiotherapy as primary therapy in 
combination with long-term ADT in patients with high PSA levels at 
diagnosis. As GS of 8-10 resulted to be the strongest predictor of 
outcome, a subgroup of patients at worse prognosis might be early 
identified, since these patients represent the ideal candidates for 
more tailored and aggressive therapies in future trials. 
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Purpose/Objective: Neo-adjuvant chemotherapy (nCT) has known 
survival benefit in the treatment of MIBC. Favourable response is 
associated with improved outcome and identifies those who may 
benefit from bladder preservation with radical radiotherapy. 
Conventionally response assessment is with cystoscopy. We report on 
the use of DW-MRI as a potential non-invasive alternative means of 
assessment and as a predictor of nCT sensitivity.  
Materials and Methods: 19 patients with confirmed MIBC suitable for 
nCT were recruited prospectively to an ethics approved protocol. DW-
MRI was performed on a 1.5T system using b-values 0,50,100,250,500 
and 750s/mm2 prior to and on completion of nCT. Tumour was drawn 
on the 750s/mm2 image and transferred onto the corresponding ADC 
map to record mean values. Following final DW-MRI patients 
proceeded to cystoscopy + biopsy. Association between nCT 
sensitivity, pre-treatment ADC, post-treatment ADC and change of 
ADC (ΔADC) was analysed. 
Results: 12 patients achieved pathological complete response, 6 
achieved partial response and 1 progressed following nCT (as assessed 
on cystoscopy and T2-weighted MRI). In 15 patients tumour was 
identified on pre-nCT DW-image. 4 patients had no measurable 
disease on pre-nCT MRI. Baseline tumour median ADC was 1.3x10-
3mm2/s (range 0.7-2.7x10-3mm2/s). 
Complete response was associated with a significant increase in 
median ADC from 1.3x10-3mm2/s (range 0.7-2.7x10-3mm2/s) to 2.2x10-
3mm2/s (range 1.9-3.2x10-3mm2/s) (p=0.036). Change in mean ΔADC 
was significantly greater in complete responders compared to 
incomplete responders; responders median ΔADC 1.1x10-3 mm2/s, 
range 0.6-1.41x10-3mm2/s; incomplete responders median ΔADC 
0.1x10-3mm2/s, range 0.03-0.3x10-3mm2/s (p=0.034). 
Pre-treatment ADC was not predictive of response to nCT.  
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Conclusions: DW-MRI is useful in assessing response in MIBC. It may be 
a potential biomarker for predicting nCT sensitivity and guide 
selection for bladder sparing approaches but further work is needed.  
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Purpose/Objective: Cancer cells exhibit increased glucose 
metabolism through an upregulation of glycolysis. Increased glycolysis 
may occur in response to hypoxia or in an oxygen-independent manner 
as a result of altered gene expression, both mediated via the HIF-1 
transcription factor. It has been shown that tumours with high levels 
of glycolysis, as indicated by high lactate concentration, are less 
responsive to radiotherapy. The goal of this pre-clinical study was to 
evaluate glycolytic targeting by HIF-1 inhibition as a strategy to 
enhance radiation response.  
Materials and Methods: Cervix (ME180) and hypopharynx (FaDu) 
xenograft tumours were grown in the hind leg of nude mice. Mice 
were placed in an environmental chamber for exposure to different 
oxygen conditions (20% or 7% inspired oxygen concentration for 3 
hours). HIF-1 inhibition was achieved by two methods: a doxycycline-
inducible HIF-1 negative mutant and lentiviral transfection of the HIF-
1 shRNA. Glycolysis was evaluated using ex-vivo quantitative bio-
luminescence microscopy of lactate concentration and distribution in 
tumour cryosections. Tumour hypoxic fraction was measured using EF5 
immunohistochemical staining. Growth delay of xenografts was 
studied following their irradiation with a single 20Gy fraction. 
Results: In air-breathing (20% oxygen) conditions, HIF-1 knockdown 
caused no significant difference in average lactate or EF5 levels or in 
tumour growth. Under conditions of hypoxia (7% oxygen), HIF-1 
inhibition produced a significant (p<0.05) reduction in average lactate 
levels compared to controls in both the ME180 and FaDu tumours (15.8 
to 12.4 μmol/g and 8.4 to 5 μmol/g respectively). The hypoxic 
fraction increased (p<0.05) with HIF-1 inhibition in both tumours 
(ME180: 0.09 to 0.13 and FaDu: 0.06 to 0.13). Tumours treated with a 
combination of HIF-1 knockdown and radiation had an increased 
growth delay compared to tumours treated with radiation alone 
(p<0.05). HIF-1 inhibition did not alter the growth of non-irradiated 
tumours.  
Conclusions: HIF-1 inhibition can reduce glycolysis and improve 
radiation response in hypoxic tumours despite an associated increase 
in the hypoxic fraction. The underlying molecular mechanisms require 
further investigation but the results suggest that HIF-1 inhibitors, by 
virtue of their effects on tumour metabolism, might be useful 
radiosensitizing agents. 
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Purpose/Objective: Diffusion-weighted magnetic resonance imaging 
(DWI) provides information about the movement of water molecules 
inside tissue. The clinical utility of DWI in gynecologic malignancies 
has steadily increased over recent years. The purpose of our study is 
to focus on the quantitative index of DWI—the Apparent Diffusion 
Coefficient (ADC) value, to investigate its role as a predictor of 
treatment response and to establish a correlation between baseline 
ADC value and outcome. 
Materials and Methods: A total of 20 patients (mean age 55.2 years) 
of squamous cell carcinoma cervix (FIGOStages IB through IIIB) who 
underwent radical chemoradiation and had a median follow up of 6 
months were included in the ADC analysis. Apparent Diffusion 
Coefficient of ten normal controls was assessed. MRI was performed 
pretreatment and 3 months after treatment on a 3T Siemens MRI unit. 
For calculation of ADC a b value of 500mm2/s was used. SPSS v 17.0 
was used for analysis. 
Results: The mean ADC of cervical carcinomas (0.76 ± 0.26 ×10-
3mm2/s) was significantly lower than normal cervix (1.45 ± 0.46×10-
3mm2/s) (P<0.001). The mean post treatment ADC values (1.40 +0.15 x 
10-3 mm2/s) at 3 months were also significantly (p<0.01) higher in 
responders (n = 17) and they remain disease free at 6 months. Mean 
post treatment ADC values were 1.05 + 0.25 x 10-3 mm2/s at 3 months 
in nonresponders. However, there was no statistically significant 
correlation seen between pre treatment mean ADC and FIGO stage, 
nodal disease or tumour volume.  
Conclusions: Baseline pretreatment ADC values are low in squamous 
cell carcinoma cervix and they show a significant change after radical 
chemoradiation in responders. Although our data is early and the 
patient numbers are small, there is indication that the absolute ADC 
value at 3 months post treatment can predict long term disease 
control and could help to identify a potential cut off value that may 
call for early clinical intervention in nonresponders.  
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Purpose/Objective: There is dearth of data on Quality of Life (QOL) in 
patients treated with Intensity Modulate Radiotherapy (IMRT) for 
cervical cancers. The present study was undertaken to quantify serial 
changes in QOL before and after postoperative IMRT. 
Materials and Methods: Patients undergoing adjuvant or salvage IMRT 
(50 Gy/25 #/ 5 wks with concurrent weekly cisplatin and vaginal 
brachytherapy) within clinical trials completed the EORTC QLQC30 
and cervix specific module (Cx-24) in EORTC validated vernacular 
language before, after, 3 and 6 months of completion of IMRT. Raw 
scores were calculated as per standard EORTC recommendations and 
final score was determined for each of the items using SPSS version 
20.0. Wilcoxon signed rank test was applied for comparison between 
different time points at follow up. In subset analysis of 23 patients 
who completed 6 months follow up general linear model was used for 
within the subject analysis of variances (ANOVA). p value <0.05 was 
considered statistically significant.  
Results: Forty patients undergoing adjuvant (n=26) and postoperative 
salvage (n=14) IMRT were included. At 3 months after completion of 
treatment, statistically significant improvement was observed across 
functional (except cognitive and social functioning) and symptom 
scales (except nausea and vomiting, dyspnoea, appetite loss and 
diarrhoea) when compared to pretreatment scores. Furthermore 
statistically significant improvement in global quality of life score 
(64.16 vs. 80.2,p=0.000). Amongst cervix specific QOL module (Cx-24) 
improvement in sexual and vaginal function was observed (85.93 vs. 
71, p=0.02). The difference in all other organ specific functional 
scores was not significant. However in symptom scale, reduction in 
